MDWD (MediWound) LT-Debt-to-Total-Asset : 0.09 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is MediWound LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. MediWound's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.09.

MediWound's long-term debt to total assets ratio declined from Dec. 2023 (0.10) to Dec. 2024 (0.09). It may suggest that MediWound is progressively becoming less dependent on debt to grow their business.

MediWound LT-Debt-to-Total-Asset Historical Data

The historical data trend for MediWound's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediWound LT-Debt-to-Total-Asset Chart

MediWound Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.07

0.02

0.10

0.09

MediWound Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	0.10	0.11	0.09	0.09

MediWound LT-Debt-to-Total-Asset Calculation

MediWound's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	6.513	/	73.496
	=	0.09

MediWound's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	6.513	/	73.496
	=	0.09

MediWound (NAS:MDWD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

MediWound LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of MediWound's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

MediWound Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediWound Ltd (NAS:MDWD) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

M8W:Germany

Address

42 Hayarkon Street, Yavne, ISR, 8122745

Website

https://www.mediwound.com

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.